BETA2-ADRENERGIC RECEPTOR DOWN-REGULATION IN ASTHMA

哮喘中的β2-肾上腺素受体下调

• 批准号: 6532638
• 负责人: Stacie M Jones
• 金额: $ 12.66万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-01 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6532638
• 关键词: asthma; beta adrenergic receptor; beta antiadrenergic agent; clinical research; genetic polymorphism; human subject; receptor expression; respiratory disorder chemotherapy; respiratory pharmacology

Dr. Stacie Jones, the PI, is an assistant professor who completed her pediatric allergy/immunology fellowship in 1994. In this proposal, she outlines a program to study the effects of prolonged beta-agonist treatment on beta2 adrenergic receptor (beta2AR) regulation in patients with asthma. Development of tolerance to beta-agonists has been a significant concern in the treatment of asthma-related bronchospasm. Both in vitro and in vivo studies have demonstrated change in beta2AR density in relation to prolonged beta-agonist exposure. Trafficking of beta2AR to lysosomes for degradation describes the process of down-regulation. Despite its importance in determining responsiveness to beta-agonists, little is known about the molecular mechanisms driving beta2AR down-regulation. This project proposes to use a novel approach employing beta2AR- apidermal growth factor receptor chimeras to define the important molecular determinants and intracellular protein interactions that are responsible for lysosomal sorting and beta2AR down- regulation following prolonged beta-agonist exposure. Information gained in the laboratory will be applied in translational research at the bedside to correlate-the cellular mechanisms responsible for beta2AR down-regulation with genetic polymorphisms of the beta2AR in asthmatics. The central hypothesis of this proposal is that beta2AR down-regulation is driven by specific interaction between a soluble intracellular protein with a beta2AR lysosomal targeting domain and that the rate of down-regulation is modified by polymorphisms in the amino-terminal region of the beta2AR. Employing a series of molecular and cellular biology techniques, the hypothesis will be tested via the following Specific Aims: 1) Identify the functional beta2AR lysosomal targeting domain driving beta2AR trafficking and define the impact of beta2AR amino-terminus polymorphisms on beta2AR down-regulation, 2) Determine the intracellular lysosomal targeting protein(s) responsible for beta2AR sorting to lysosomes, and 3) Assess the clinical relevance of beta2AR polymorphisms in receptor trafficking and down-regulation in asthmatics in the setting of prolonged agonist exposure. Information gained from the proposed studies will advance our knowledge of the association between beta-agonist exposure and beta2AR down-regulation and may led to new approaches in asthma therapeutics. The PI will take advantage of the strong mentoring, protected research time and the outstanding academic resources of the University of Arkansas for Medical Sciences to reach her goal of becoming an independent investigator.

Stacie Jones博士是一名助理教授，于1994年完成了儿科过敏/免疫学研究。 在这份提案中，她概述了一项研究长期β受体激动剂治疗对哮喘患者β 2肾上腺素能受体（β 2AR）调节的影响的计划。 对β受体激动剂耐受性的发展一直是哮喘相关支气管痉挛治疗中的一个重要问题。 体外和体内研究均表明，β 2 AR密度的变化与β激动剂长期暴露有关。 β 2 AR运输至溶酶体进行降解描述了下调过程。 尽管它在确定β受体激动剂的反应性方面很重要，但对驱动β 2AR下调的分子机制知之甚少。 该项目提出使用一种采用β 2 AR-表皮生长因子受体嵌合体的新方法来确定重要的分子决定簇和细胞内蛋白相互作用，这些决定簇和细胞内蛋白相互作用负责溶酶体分选和β 2 AR在长时间β激动剂暴露后的下调。实验室获得的信息将应用于床边的转化研究，以将哮喘患者中β 2AR下调的细胞机制与β 2AR的遗传多态性相关联。 该提议的中心假设是β 2 AR下调是由可溶性细胞内蛋白与β 2 AR溶酶体靶向结构域之间的特异性相互作用驱动的，并且下调速率由β 2 AR氨基末端区域的多态性修饰。 采用一系列分子和细胞生物学技术，将通过以下特定目的对假设进行检验：1）鉴定驱动β 2 AR运输的功能性β 2 AR溶酶体靶向结构域，并确定β 2 AR氨基末端多态性对β 2 AR下调的影响，2）确定负责β 2 AR分选至溶酶体的细胞内溶酶体靶向蛋白，和3）评估β 2 AR多态性在受体运输和下调中的临床相关性，在长期激动剂暴露的情况下。 从拟议的研究中获得的信息将推进我们对β激动剂暴露和β 2AR下调之间关系的认识，并可能导致哮喘治疗的新方法。PI将利用阿肯色州大学医学科学学院强大的指导、受保护的研究时间和优秀的学术资源，实现成为独立研究者的目标。